Trump’s tariffs are raising healthcare costs across the board—and the bills are already hitting American wallets. In 2026 alone, health insurance premiums on the ACA Marketplace are rising 18%, the largest increase in 15 years, with tariffs accounting for an additional 3 percentage points of that jump. A 45-year-old person buying individual coverage could see their premium increase by hundreds of dollars per month.
Beyond insurance, pharmaceutical tariffs hit even harder: a new 100% tariff on patented drugs will push national drug costs up by an estimated $51 billion annually, while medical devices like feeding tubes face tariffs as high as 245%. The human impact is concrete—people with chronic conditions like diabetes, heart disease, or rare genetic disorders will see medication costs spike, while hospitals will absorb or pass on massive supply chain costs. This article breaks down exactly how tariffs flow through the healthcare system and what it means for your out-of-pocket costs.
Table of Contents
- How Tariffs Are Driving Up Health Insurance Premiums
- The Pharmaceutical Tariff Impact and Drug Price Explosion
- Medical Devices and Hospital Supply Chain Pressures
- Real-World Impact on Patient Out-of-Pocket Costs
- The Onshoring Trade-off—And Why It May Not Solve the Problem
- Vulnerable Populations Face the Hardest Hit
- Timeline and What to Expect Through 2026
- Conclusion
How Tariffs Are Driving Up Health Insurance Premiums
The 18% premium increase announced for 2026 marketplace plans represents a dramatic acceleration in healthcare costs. For context, premiums rose just 7% from 2024 to 2025—meaning the tariff-driven jump adds roughly 11 additional percentage points of inflation. Health insurers are explicit about the cause: they’re passing through the cost of importing medical devices, pharmaceuticals, and raw ingredients under higher tariffs. The Kaiser Family Foundation analysis found that tariffs account for approximately 3 percentage points of the 18% increase on average, though some insurers cite even larger impacts.
For a family of four on an ACA plan, this could mean an additional $1,200 to $2,400 per year in premiums alone, before accounting for deductibles and out-of-pocket expenses. What makes this particularly damaging is the timing. Employer-sponsored insurance saw its largest increase in 15 years, suggesting that tariff impacts extend far beyond the marketplace into group health plans as well. Employers are absorbing some of these costs, but many are shifting them to workers through higher employee contributions and deductibles. Someone earning $50,000 a year and receiving employer coverage may see their take-home pay shrink by $30-50 per paycheck just to cover premium increases—without any improvement in actual healthcare quality or access.
The Pharmaceutical Tariff Impact and Drug Price Explosion
On April 2, 2026, the trump administration imposed a 100% tariff on patented pharmaceutical products and imported active pharmaceutical ingredients, a move that dwarfs the insurance premium increases in terms of absolute dollar impact. The Ernst & Young analysis estimated this tariff level alone will add $51 billion in annual drug costs nationally. To put this in perspective: that’s roughly the annual healthcare budget for every person on Medicaid in a mid-sized state. The tariff takes effect in 120 days for large pharmaceutical companies and 180 days for smaller manufacturers, meaning most patients will begin experiencing higher prices by mid-2026. However, the White House structured the tariff with negotiation pathways that could reduce or eliminate the burden—but only for companies willing to accept restrictions.
Manufacturers that negotiate Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services and agree to onshore production with the Department of Commerce can secure a 0% tariff rate. EU, Japan, Korean, Swiss, and Liechtenstein products face a reduced 15% tariff. The catch: these are concessions that require companies to accept lower profit margins and commit capital to U.S. manufacturing. Generic drug manufacturers, who already operate on thin margins, have limited ability to negotiate these deals, meaning generic prices will likely rise faster than brand-name drugs that can more easily absorb onshoring costs.
Medical Devices and Hospital Supply Chain Pressures
Medical device tariffs are more targeted but far more extreme in some categories. Enteral syringes—sterile feeding tubes used for patients who cannot eat normally, including cancer patients, stroke survivors, and people with swallowing disorders—face a 245% tariff. This is among the most punitive tariffs in the healthcare sector, and it reflects a supply chain reality: few alternative suppliers exist for specialized medical devices, limiting manufacturers’ ability to source products domestically.
A hospital system that previously purchased feeding tubes at $0.50 per unit may now face prices of $1.73 per unit if tariffs push through to buyers. A Medical Economics survey found that 82% of physicians expect tariff-related import costs will increase hospital and health system expenses by 15% within six months. For context, hospital operating margins typically run 2-3%, meaning a 15% cost increase forces difficult choices: cut services, reduce staff, defer maintenance on equipment, or pass costs directly to patients through higher copays and out-of-pocket maximums. Smaller rural hospitals and safety-net hospitals that serve uninsured and Medicaid populations face the tightest squeeze, since they cannot easily raise prices and have limited access to capital for equipment upgrades or tariff mitigation.
Real-World Impact on Patient Out-of-Pocket Costs
The tariff impacts hit patients at the moment they are most financially vulnerable—when they need healthcare. A patient with type 2 diabetes on metformin and a GLP-1 receptor agonist could see their monthly medication costs rise $100-200 if the 100% pharmaceutical tariff fully passes through. For someone already paying $200-300 per month in copays and coinsurance, this is the difference between buying medication and buying groceries.
Patients in states with high insurance premiums—California, Florida, and New York are already experiencing double-digit increases—face a compounding cost shock: premium increases, plus higher deductibles (insurers often raise deductibles to offset premium costs), plus higher drug prices. A specific example: a 55-year-old woman with rheumatoid arthritis using a biologic medication (cost: ~$2,000 per month) who pays 25% coinsurance would previously owe $500 per dose every three weeks. If tariffs drive the wholesale price to $2,500, her coinsurance jumps to $625—a 25% increase on top of any premium hike. Over a year, she absorbs an extra $1,500 in out-of-pocket costs, which could force her to skip doses, split pills, or forgo preventive care to balance her healthcare budget.
The Onshoring Trade-off—And Why It May Not Solve the Problem
The White House framed tariffs as leverage to pull pharmaceutical manufacturing back to the United States, citing $400 billion in announced investment commitments from U.S. and foreign pharmaceutical companies to establish or expand U.S. production. This is a legitimate long-term supply security argument: during the COVID-19 pandemic and in recent global disruptions, U.S. dependence on imported active pharmaceutical ingredients and finished drugs exposed critical vulnerabilities. Building domestic capacity reduces that risk.
The catch is timing and realistic expectations. A new pharmaceutical manufacturing facility takes 3-5 years to build and FDA-validate, meaning the tariffs imposed in April 2026 will burden patients and hospitals for years before any meaningful domestic production capacity comes online. Moreover, not all drugs can be economically manufactured in the U.S.; some require rare raw materials, specific climate conditions, or labor-intensive processes that favor low-cost manufacturing countries. The tariff leverage may not produce as much onshoring as projected—some companies may simply accept the tariff cost and continue importing, while others may offshore to tariff-exempt countries. And even if onshoring succeeds, it will not inherently lower prices; it may simply shift profits from Indian and Chinese manufacturers to U.S. manufacturers with no benefit to patients.
Vulnerable Populations Face the Hardest Hit
Certain groups face disproportionate harm from healthcare tariffs. People on fixed incomes—seniors on Medicare, disabled individuals on SSI—often have limited ability to absorb premium increases or higher out-of-pocket costs. A senior whose total monthly income is $1,800 cannot simply accept a $400 annual insurance premium increase without cutting food, utilities, or other essentials. Medicaid beneficiaries in states that did not expand Medicaid coverage are already excluded from ACA subsidies and marketplace coverage; they face higher tariff-driven costs with no offsetting tax credits.
Patients with rare diseases or complex conditions requiring specialty pharmaceuticals are at extreme risk. A patient with cystic fibrosis or a rare genetic disorder may depend on a single drug with few or no generic alternatives. When tariffs hit those drugs with a 100% rate, there is no workaround—patients cannot switch to a cheaper option or negotiate a lower price directly with the manufacturer. These populations may face rationing decisions at the pharmacy counter they should never have to contemplate.
Timeline and What to Expect Through 2026
The tariff impacts will roll out in waves. Insurance premium increases are already locked in for 2026 coverage year plans, so those changes are non-negotiable for anyone renewing coverage after May 1, 2026. Pharmaceutical tariffs take effect in 120 days (by early July 2026) for large companies and 180 days (by late September 2026) for smaller manufacturers, meaning drug price increases will accelerate over the summer and fall. Medical device tariffs are already in effect as of April 2, 2026, so hospitals and medical suppliers are already absorbing higher costs and beginning to pass them through to patients.
The question ahead is whether Congress or the administration will adjust course. If tariff revenue becomes politically untenable—because seniors are cutting medications, or rural hospitals begin closing because of supply chain costs—exemptions or reductions may follow. However, no such relief is currently on the horizon. Patients and providers should expect persistent, cumulative cost increases through 2026 and into 2027 as tariff impacts fully propagate through the system.
Conclusion
Trump’s tariff regime is raising healthcare costs across every dimension: insurance premiums, prescription drugs, and medical devices. The 18% marketplace premium increase, 100% pharmaceutical tariff, and device tariffs as high as 245% represent a substantial financial burden on American households and healthcare institutions. While the administration argues these tariffs protect supply chains and incentivize domestic manufacturing, the near-term pain is real and unavoidable—people will pay more for insurance, pay more for medications, and receive less timely and affordable care. If you are purchasing insurance for 2026, expect higher premiums and plan accordingly.
If you rely on prescription medications, ask your doctor whether generic alternatives or therapeutic substitutes exist that may help manage costs. If you work for a hospital or clinic, understand that supply chain costs will likely be passed through to patients. And if you are among the millions of Americans already struggling with healthcare affordability, prepare to make harder trade-offs between medication, food, and other essentials. The economic impacts of tariffs on healthcare are just beginning to manifest, and households should budget accordingly.